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functional improvement on all scales. Post-group treat-
ment effects were maintained at follow-up with the excep-
tion of emotional control and the Total composite scales, 
which continued to improve. The largest treatment effect 
was for the RATE-S Total composite scale, associated with 
life satisfaction. CGI significantly correlated with all out-
comes except for social functioning scale at follow-up. The 
study provides further evidence for the effectiveness of 
R&R2ADHD and demonstrates the importance of measur-
ing functional outcomes. The key mechanism associated 
with improved functional outcomes is likely to be behav-
ioural control.
Keywords ADHD · RCT · Treatment · Reasoning and 
rehabilitation · R&R2 · Cognitive behaviour therapy
Introduction
Attention deficit/hyperactivity disorder (ADHD) is a 
common disorder of childhood that, for many, persists 
into adulthood [1]. The disorder is characterized by core 
symptoms of inattention, hyperactivity and/or impulsivity 
defined in DSM-5 [2] and ICD-10 [3]. Those diagnosed 
with the disorder display impairments in their personal and 
social functioning (e.g. educational attainment, occupa-
tional difficulties and relationship problems) [4].
ADHD may be lifelong disorder that has a profound 
effect on an individual’s quality of life. Biederman et al. 
[5] conducted a 16-year follow-up of 140 boys with 
ADHD into their thirties and compared them with 120 
boys without ADHD of a similar age. They found that the 
ADHD cohort had greater impairment in social function-
ing and daily living. In particular, they had greater family 
conflict, dependence on parents for financial support and 
Abstract Studies assessing psychological treatment of 
attention deficit hyperactivity disorder (ADHD) in adults 
are increasingly reported. However, functional outcomes 
are often neglected in favour of symptom outcomes. We 
investigated functional outcomes in 95 adults with ADHD 
who were already treated with medication and randomized 
to receive treatment as usual (TAU/MED) or psychologi-
cal treatment (CBT/MED) using a cognitive–behavioural 
programme, R&R2ADHD, which employs both group and 
individual modalities. RATE-S functional outcomes associ-
ated with ADHD symptoms, social functioning, emotional 
control and antisocial behaviour were given at baseline, 
end of treatment and three-month follow-up. The Total 
composite score of these scales is associated with life satis-
faction. In addition, independent evaluator ratings of clini-
cians who were blind to treatment arm were obtained on 
the Clinical Global Impression scale at each time point. 
CBT/MED showed overall (combined outcome at end of 
treatment and 3-month follow-up) significantly greater 
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lower socio-economic status. The risk of impaired func-
tional outcomes seems to be considerably greater for young 
people with ADHD who do not receive treatment. By ana-
lysing the data derived from 351 studies, Shaw et al. [6] 
reported that, compared to people without ADHD, 74 % of 
functional outcomes were worse for people with untreated 
ADHD. However, with treatment, 72 % of functional out-
comes improve over the longer term. Domains of self-
esteem, social function, academic performance and antiso-
cial behaviour may respond particularly well to multimodal 
treatments that combine both pharmacological and non-
pharmacological modalities [4].
A range of intervention strategies is available to treat 
children and adults with ADHD, including psychological 
and pharmacological interventions. International guidelines 
recommend a multimodal treatment approach comprising 
both pharmacological and psychological interventions [7], 
and there is empirical support for a larger treatment effect 
for functional outcomes when using a combined approach 
over the longer term [4]. Psychological treatments in 
adults have generally been based on cognitive–behavioural 
therapy (CBT) [8]. Group interventions are attractive for 
clinical delivery as they are cost-effective as well as dem-
onstrating medium to large treatment effects for the reduc-
tion in ADHD symptoms in randomized control trials of 
medicated ADHD patients [9–15]. However, most studies 
typically focus on clinical outcomes rather than functional 
outcomes as primary measures of success, yet the latter are 
important markers of treatment efficacy due to their trans-
lational value, i.e. because they often relate to functional 
activities of daily living.
Young and Gudjonsson [16] demonstrated that func-
tional impairments associated with neuropsychological 
test scores, clinical symptoms of anxiety and depression, 
and psychosocial performance are all significantly related 
to underlying ADHD symptoms but, for some individuals, 
these impairments improve with remission of symptoms. 
However, for others, residual problems will persist with 
patients seeking psychiatric help in adulthood. Gudjonsson 
et al. [17] investigated the relationship between satisfac-
tion with life, ADHD symptoms and associated functional 
problems measured by the RATE-S (emotional, social and 
antisocial) among young people in the community. ADHD 
symptoms and associated problems were significantly 
related to less satisfaction with life. Poor social function-
ing was the single best predictor of dissatisfaction with life 
in males, whereas in females it was poor emotional con-
trol. The study shows that even in samples where only mild 
ADHD symptoms were identified, satisfaction with life is 
adversely affected. The Total RATE-S scale was overall the 
best predictor of satisfaction with life.
A study conducted by Emilsson et al. [12] reported sig-
nificant and large treatment effects at 3-month follow-up 
for functional outcomes (assessed by the RATE-S scales) 
for each of its four subscales (ADHD symptoms, emo-
tional control, antisocial behaviour and social functioning) 
and the total score. However, their study only involved 54 
participants, 27 in each group, and there was a substantial 
amount of missing data at the end of treatment and at three-
month follow-up for both the CBT/MED and TAU/MED 
groups which may have led to a biased estimate of the 
treatment effect. To reduce possible bias, White et al. [18] 
recommend analysing all the observed outcome data via 
the maximum likelihood method under missing data ran-
dom (MAR) assumption. This requires the inclusion of any 
relevant predictors of missing data in the analysis model.
The present study aimed to investigate functional out-
comes of a multimodal treatment provided to adults with 
ADHD who were receiving medication and were rand-
omized to receive CBT/MED or treatment as usual (TAU/
MED). We have previously reported clinical outcomes 
[15], and in this study we report functional outcomes using 
the RATE-S scales [19] which were developed to assess 
attention, social functioning, emotional control and antiso-
cial behaviour. Outcomes were assessed post-group and at 
three-month follow-up. The RATE-S Total composite scale 
is associated with satisfaction [17]. We performed an inten-
tion-to-treat analysis using a linear mixed model and ana-
lysed for three possible predictors of missing data: gender, 
age and antisocial personality traits. Thus, we analysed the 
effects of treatment over time (i.e. end of treatment versus 
at three-month follow-up) as well as overall group differ-
ences in the outcome measures whilst controlling for pos-
sible group imbalances caused by missing data.
It was hypothesized that the CBT/MED group would 
show significantly greater functional improvement com-
pared with the TAU/MED group (after adjusting for miss-
ing data and possible confounders) in the RATE-S Total 
composite scale and across each of the four RATE-S scales 
(ADHD symptoms, emotional control, antisocial behav-
iour and social functioning). Second, treatment gains were 
expected to be maintained at three-month follow-up. Third, 
it was hypothesized that functional outcomes on the RATE-
S would correlate with independent evaluator ratings of the 
Clinical Global Impression assessment of illness severity.
Method
Trial design
This study has been described in detail in our previous 
study reporting clinical outcomes [15]. Briefly, a parallel-
group RCT was conducted at an ADHD outpatient setting 
within the Mental Health Services at Landspitali—The 
National University Hospital of Iceland. All participants 
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meeting inclusion criteria were independently and individ-
ually randomly allocated (1:1) to receive the R&R2ADHD 
programme (CBT/MED) or treatment as usual (TAU/
MED). Assessments occurred at three time points: baseline, 
end of treatment and 3 months after treatment. The study 
was registered with the international clinical trials registry 
(ACTRN12611000533998).
Participants
Participants were outpatients at the Mental Health Services 
at the Landspitali University Hospital, referrals from private 
practitioners or self-referrals from an advertisement placed 
with a national ADHD support group (Icelandic ADHD 
Association). Participants were over 18 years of age, had a 
current ADHD diagnosis and reported they had remained 
stable on prescribed ADHD medication for at least 1 month. 
It was requested that the participants kept their medication 
dosages unchanged during the study. Exclusion criteria 
included severe mental illness (i.e. psychotic disorders, bipo-
lar disorder), active suicidal ideation, severe eating disorder, 
history of drug abuse and general intellectual impairment as 
without modification the treatment programme would not 
be suitable for these patient groups. Exclusion criteria were 
evaluated from a review of the patient’s medical record and a 
baseline assessment by an experienced mental health practi-
tioner (see baseline assessments section).
A total of 187 patients were referred and out of those 
95 (51 %) participated in the study. Figure 1 provides the 
reasons for non-participation. Eleven participants were 
excluded because at the intake interview they did not meet 
DSM-IV diagnostic criteria; 62 (65.3 %) of the participants 
were female (mean age = 35.00, SD = 11.81); and 33 
(34.7 %) were male (mean age = 35.45, SD = 11.62).
Table 1 gives the demographic and clinical characteris-
tics of the study sample. Psychiatrists prescribed medica-
tion at baseline; 79 (83.2 %) were prescribed methylpheni-
date; and 16 (16.8 %) atomoxetine. Five participants were 
also taking bupropion. In addition, 63 (66.3 %) participants 
were taking other prescribed medications including antide-
pressants, benzodiazepines, insulin and ibuprofen.
In addition to ADHD, participants reported comorbid 
depression (63.2 %), anxiety (36.8 %) and history of drug/
alcohol abuse (15.8 %). Seven participants (7.4 %) reported 
that they had been diagnosed with a personality disorder 
and four (4.2 %) with Asperger’s syndrome in childhood. 
Four (4.2 %) reported having post-traumatic stress disorder 
(PTSD) and two (2.1 %) with a history of eating disorder.
Interventions
R&R2ADHD is a CBT intervention programme devel-
oped for youth and adults with ADHD [20]. It is a revised 
version of the 35-session Reasoning & Rehabilitation 
prosocial competence training programme which has a 
strong evidence base [21]. It was revised to be a shorter 
and more relevant intervention for individuals present-
ing with symptoms associated with ADHD. The revision, 
R&R2ADHD, is a structured, manualized programme con-
sisting of fifteen 90-minute sessions (excluding a mid-ses-
sion break) five treatment modules: (a) neurocognitive, e.g. 
learning strategies to improve attentional control, memory, 
impulse control and planning; (b) problem solving, e.g. 
developing skilled thinking, problem identification, conse-
quential thinking, managing conflict and making choices; 
(c) emotional control, e.g. managing feelings of anger and 
anxiety; (d) prosocial skills, e.g. recognition of the thoughts 
and feeling of others, empathy, negotiation skills and con-
flict resolution; and (e) critical reasoning, e.g. evaluating 
options and effective behavioural skills. R&R2ADHD is 
a group treatment supplemented by one-to-one meetings 
with a mentor. In the present study, the group sessions 
were delivered twice per week (i.e. with a total duration of 
8 weeks). The mentors met with the participants between 
each group session in order to support participants to trans-
fer skills learned in the group into their daily lives. Pro-
gramme integrity was ensured by regular supervision from 
the programme author (SY). Furthermore group sessions 
were delivered according to the manual by experienced 
CBT therapists who had received training and accreditation 
to deliver the programme. The mentoring sessions were 
provided by psychology students who also received train-
ing, supervision and written guidance.
Treatment as usual was classified as receiving usual treat-
ment, which included both pharmacological and non-phar-
macological treatments. All participants received ADHD 
medication, but non-pharmacological interventions were 
not systematically recorded.
Measures
Baseline assessments
All of those referrals who could be contacted and who con-
sented to participate in the study were interviewed by an 
experienced mental health practitioner prior to randomi-
zation to ascertain clinical diagnosis according to DSM-
IV criteria using the MINI International Neuropsychiatric 
Interview [22]. In addition, the 54-item Gough Socializa-
tion Scale [23] was used to measure antisocial personal-
ity (ASP) traits. ASP traits have been commonly found 
in outpatients diagnosed with ADHD [24] and have been 
associated with failure to attend follow-up appointments 
after treatment and hence may relate to missing follow-up 
data [25]. Socio-demographic data and medical informa-
tion from a review of clinical records were obtained (see 
 Eur Arch Psychiatry Clin Neurosci
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Table 1). IQ scores were not systematically recorded in the 
clinical records, but individuals were excluded if reference 
was made to general intellectual impairment. In addition, 
a battery of measures that were completed by either self-
report or by the independent evaluator was administered. 
Those relating to the present study are:
1. The RATE-S [19] is a revision of the YAQ-S scale [26] 
representing the 8 items with the highest factor loading 
from each of the four YAQ-S subscales. It has 32 self-
reported items relating to functioning and behaviour in 
the past month. It consists of four subscales: (1) ADHD 
symptoms (i.e. items relating to attentional difficul-
187 referred to the study
92 Excluded following clinical assessments (49%)
• 30 declined participation (33%)
• 18 could not be contacted (20%)
• 16 no longer on medication (17%)
• 11 did not receive an ADHD diagnosis (12%)
• 8 active substance misuses (9%)
• 7 did not attend assessment (8%)
• 2 under the age of 18 (2%)
End of treatment
35 Completed either self-reports or independent 
evaluations (73%):
33 Completed independent evaluations (69%)
34 Completed self-reports (71%)
Baseline
48 Intake interviews:
47 Completed independent evaluations (98%)
46 Completed self-reports (96%)
48 Allocated to CBT/MED condition
Baseline
47 Intake interviews:
45 Completed independent evaluations(96%)
46 Completed self-reports (98%)
47 Allocated to TAU/MED condition
End of treatment
39 Completed either self-reports or independent 
evaluations (83%):
34Completed independent evaluations (72%)
35 Completedself-reports (74%)
Follow-up
27 Completed either self-reports or independent 
evaluations measures (56%):
21 Completed independent evaluations (44%)
25 Completed self-reports (52%)
Follow-up
32 Completed either self-reports orindependent 
evaluations (68%):
27 Completed independent evaluations (57%)
32 Completed self-reports (68%)
95 Randomized (51%)
Fig. 1  Flow chart of patient participation
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ties, impulsiveness and disorganization), (2) emotional 
control (i.e. items relating to emotional volatility and 
include worries, anxieties, depressed mood, anger, loss 
of temper and poor self-esteem), (3) antisocial behav-
iour (i.e. involvement in a range of delinquent behav-
iours’ such as fighting, theft, damage to property, van-
dalism, reckless behaviour, verbal threats to others, and 
being arrested and questioned by police), and (4) social 
functioning (i.e. items focus on social participation and 
confidence in social activities). Behaviours during the 
previous month are rated on an 8-point scale, ranging 
from “not at all” to “most of the time”. All scales have 
shown good internal consistency, as measured by Cron-
bach’s alpha (i.e. exceeding 0.80 both for people with 
ADHD and for normal controls). The scales also dem-
onstrate a good discrimination between ADHD patients 
and clinical controls [26] and a good construct validity, 
both for patients and for controls [24]. In the Icelandic 
translation of the RATE-S scale, the measure has dem-
onstrated good reliability and validity [17, 27].
2. Clinical Global Impression [28] consists of a single-
question observer rating of severity of illness on a 
7-point scale. It focuses on judgment regarding impair-
ment in functioning, symptom severity and distress or 
coping and is supported by examples of these factors. 
Clinicians who were blind to treatment condition com-
pleted the CGI, which has been widely used in treat-
ment evaluation studies and found to correlate with 
ADHD severity measured by the adult ADHD investi-
gator symptom rating scale [29].
Procedure
A battery of self-rated and clinician-rated evaluations (the 
latter being blind to treatment allocation) was completed 
at the three time points (baseline, post-treatment and three-
month follow-up). Participants were randomized to either 
the CBT/MED or TAU/MED condition by a psychiatrist 
at Landspitali University Hospital, who was not involved 
in the study. The psychiatrist did not posses informa-
tion about the participants and had received numbers that 
were pre-assigned to the participants. Block randomi-
zation was performed at the time of each study phase by 
using equal block sizes. The researchers only received the 
final randomization numbers to protect the concealment of 
the allocation as proposed in various studies [30, 31]. The 
R&R2ADHD programme was delivered twice per week by 
experienced CBT therapists who had received training to 
deliver the programme. Group participants met their men-
tor for at least 30 min between group sessions. Mentors 
Table 1  Demographic, clinical and baseline characteristics of the study sample (n = 95)
* Other medications include for example antidepressants, benzodiazepines, insulin and ibuprofen
Total
n = 95
CBT/MED
n = 48
TAU/MED
n = 47
Statistics
Gender and age
 Men
 Women
 Age
 Age range
33 (43.7 %)
62 (65.3 %)
M = 35.17 (SD = 11.68)
18–73
18 (37.5 %)
30 (62.5 %)
M = 34.19 (SD = 10.58)
18–68
15 (31.9 %)
32 (68.1 %)
M = 36.17 (SD = 12.75)
18–73
χ2 = 0.327; p = 0.57
t(93) = − 0.826; p = 0.41
Marital status
 Single
 In relationship
47 (49.5 %)
47 (49.5 %)
23 (48.9 %)
24 (51.1 %)
24 (51.1 %)
23 (48.9 %)
χ2 = 0.189; p = 0.66
Employment status
 Employed
 Training
 Pension/unemployed
41 (43.2 %)
22 (23.2 %)
32 (33.7 %)
18 (37.5 %)
14 (29.2 %)
16 (33.3 %)
23 (48.9 %)
8 (17.0 %)
16 (34.0 %)
χ2 = 2.236; p = 0.33
Medical history
 History of serious illness
 History of head trauma
 History of serious accidents
 History of receiving psycho-
therapy
27 (28.4 %)
36 (37.9 %)
33 (34.7 %)
69 (72.6 %)
13 (27.1 %)
19 (39.6 %)
17 (35.4 %)
33 (68.8 %)
14 (29.8 %)
17 (36.2 %)
16 (34.0 %)
36 (76.6 %)
χ2 = 0.085; p = 0.77
χ2 = 0.118; p = 0.73
χ2 = 0.020; p = 0.89
χ2 = 0.735; p = 0.39
ADHD-specific medication
 Methylphenidate
 Atomoxetine
 Bupropion
 Other medications*
73 (83.2 %)
16 (16.8 %)
5 (5.3 %)
63 (66.3 %)
40 (83.3 %)
8 (16.7 %)
3 (6.3 %)
32 (66.7 %)
33 (83.0 %)
8 (17.0 %)
2 (4.3 %)
31 (66.0 %)
χ2 = 0.002; p = 0.963
χ2 = 0.002; p = 0.963
χ2 = 0.234; p = 0.629
χ2 = 0.005; p = 0.942
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had attended a training session to fulfil this role, which 
involved an introduction to the programme and the men-
toring role. In addition, mentors had a manual that guided 
them through topics to be discussed within the mentor-
ing session. They were provided with supervision once a 
fortnight from the lead group therapist. There were a total 
of five R&R2ADHD treatment groups. Participants in the 
TAU/MED condition received pharmacological interven-
tion and some non-pharmacological interventions, but these 
were not systematically provided or recorded.
Statistical analyses
The statistical analysis first involved applying a logistic 
regression model to identify factors (i.e. age, gender and 
antisocial personality traits) that might predict the probabil-
ity of missing data. Only age was significantly associated 
with the probability of dropouts (i.e. younger participants 
more often failed to attend the assessment interviews with 
the independent raters (CGI, Z = −2.35, p = 0.019).
An intention-to-treat analysis (i.e. individuals analysed 
in the group to which they were randomized to) of available 
outcome data was subsequently performed to estimate the 
effect of offering the treatment using a linear mixed model 
whilst controlling for age. The random component of the 
mixed model included random intercept term for partici-
pant identifier to take account of between participant vari-
ability and the correlation between the repeated measures. 
Within the fixed part of the model, the treatment effect 
was adjusted for time (i.e. a binary indicator of whether an 
outcome measure corresponds to follow-up or end of treat-
ment) and the baseline measures of the respective outcome 
in all models. We also tested condition by time interactions, 
but none were found statistically significant and therefore 
were excluded from the model.
There was minimal amount of missing data at baseline, 
but there was a substantial proportion (i.e. 37 % and 48 % 
for the RATE-S and CGI, respectively) of missing data in 
the completion of the outcome measures due to study drop-
outs. The dropout rate was similar for CBT/MED and TAU/
MED groups (see Fig. 1) with χ2 tests showing no signifi-
cant differences between groups.
Two approaches are typically recommended for dealing 
with the risk of potential bias due to missing data: the mul-
tiple imputation and complete case analysis via maximum 
likelihood. Since missing data only occurred in the out-
come variables, the complete case analysis via maximum 
likelihood was the most appropriate method. We therefore 
adopted the complete case analysis approach under a miss-
ing at random (MAR) assumption. Covariates predicting 
missingness were identified using a logistic regression 
analysis, and an analysis of all observed outcome data 
was performed using linear mixed model via maximum 
likelihood method controlling for predictors of missing 
data, which should produce unbiased estimates under MAR 
assumption [18].
Adjusted effect sizes, using Cohen’s d, were obtained by 
calculating the residuals from the respective linear mixed 
model with the condition term excluded and then calculat-
ing the standardized mean difference of the adjusted out-
come (residuals) between groups. This calculation was con-
ducted using the user contributed Stata module COHEND 
[32], which adjusts for uneven group sizes. Table 1 provides 
descriptive characteristics of the demographic and clinical 
sample data as well as the outcome measures presented in 
the form of means and standard deviations. To detect dif-
ferences between CBT/MED and TAU/MED condition at 
baseline, independent sample t tests were performed and χ2 
tests were used to analyse categories and categorical data, 
respectively.
No significant differences were found between the CBT/
MED and the TAU/MED groups in the demographic back-
ground data.
Results
Baseline characteristics
Table 2 shows that there were no significant differences 
between the CBT/MED and the TAU/MED groups in the 
baseline outcome measures regarding the RATE-S and 
CGI.
Outcomes
Table 3 provides an output from the linear mixed model anal-
yses for the RATE-S. Each row shows the coefficient of the 
treatment indicator (0 = TAU/MED, 1 = CBT/MED) and 
the relevant inferential statistics of the named outcome vari-
able. All models included a random intercept term for subject 
identification and controlled for age of participants, time of 
outcome (indicator of whether the measurement corresponds 
to end of treatment or follow-up or end of treatment) and the 
baseline measurement differences of each respective outcome 
variable. Estimates are provided of the adjusted overall mean 
differences (i.e. combining the scores from end of treatment 
and at three-month follow-up between the CBT/MED and 
TAU/MED groups and the corresponding p-values).
There was a significant main effect for all the RATE-S 
outcomes, suggesting that the CBT group had significantly 
reduced scores compared to the TAU group at end of treat-
ment. Significant differences emerged between groups on 
all the outcome variables with low (emotional control and 
social functioning) to medium (Total, ADHD symptoms, 
antisocial behaviour) effect sizes.
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There was an overall effect of time (end of treatment 
versus three-month follow-up) adjusted for baseline, 
group and age, for the emotional control scale (Z = −2.01, 
p = 0.04, d = 0.32) and the Total scale (Z = −2.19, 
p = 0.028, d = 0.54) showing steady improvement over 
time in the treatment group.
Table 4 shows that there was a significant correlation 
between the CGI and RATE-S scores at baseline, end of 
treatment and follow-up, mostly with medium to large 
effects sizes, with two exceptions. The Antisocial scale 
did not correlate significantly with the CGI scale at the 
end of treatment; nor did social functioning at follow-up. 
The correlations were overall most marked for the RATE-
S Total scale.  
Discussion
Arnold et al. [4] emphasize the importance of investigat-
ing improvements in the personal and social functioning of 
people treated for ADHD rather than merely focusing on 
changes in their core symptoms. This was the primary aim 
of the current study: investigating the functional outcomes 
(ADHD symptoms, social functioning, emotional control, 
antisocial behaviour and a general composite Total Scale) 
of a multimodal treatment provided to adults with ADHD 
(R&R2ADHD) who were receiving medication and ran-
domized to receive CBT/MED or treatment as usual. The 
study employed a linear mixed model to control for con-
founders associated with missing data, between subject 
variability and the correlation between the measures over 
time. The treatment effect in the model was adjusted for 
time, which allowed us to investigate whether or not the 
treatment effectiveness noted at the end of treatment was 
maintained or improved at three-month follow-up, in addi-
tion to investigating the overall effect of the end of treat-
ment and three-month follow-up combined.
As hypothesized, the CBT/MED group showed an 
overall significant treatment effect (i.e. the RATE-S Total 
composite scale) with a medium effect size. In addition, 
there were significant effects on all four subscales, with 
medium effect sizes being noted for the ADHD and Anti-
social scales. Hence, the perception of group participants 
was that they had experienced significantly greater func-
tional improvement at the end of the group treatment com-
pared with those receiving TAU. Importantly, the findings 
show that there were both significant group effects and 
time effects with the treatment effect being maintained at 
three-month follow-up for all scales except for emotional 
control and Total composite scales which continued to 
improve after the group had ended. This supports previ-
ous findings that anxiety, depression and quality of life also 
continue to improve over time following group completion 
[15] and extends those findings by showing that clinical 
improvements translate into daily activities and behaviours. 
Future research should include functional outcomes that 
are assessed at follow-up as well as post-treatment in order 
to capture some benefits of treatment that may present later 
due to the apparent time lag for some outcomes.
The hypothesis that functional outcomes on the RATE-S 
would correlate with independent evaluator ratings of the 
CGI assessment of illness severity was supported at base-
line, end of treatment and follow-up with the exception of 
the social functioning scale at follow-up. Large effect size 
Table 3  Estimated treatment 
effect from the linear mixed 
model analyses with adjusted 
effect sizes (Cohen’s d) from 
the model
Outcome Coef.(β) Standard error p value 95 % CI Effect size (d)
RATE-S
Total Score
−16.98 4.04 <0.001 (−24.90, − 9.06) 0.54
RATE-S
ADHD symptoms
−5.64 1.58 <0.001 (−8.75, − 2.53) 0.55
RATE-S
Emotional control
−4.61 1.92 0.017 (−8.38, − 0.84) 0.32
RATE-S
Antisocial scale
−1.4 0.43 0.001 (−2.24, − 0.56) 0.50
RATE-S
Social functioning
−5.31 1.48 <0.001 (−8.21, − 2.41) 0.41
Table 4  Correlations between the Clinical Global Impression (CGI) 
scale at three time periods with the relevant RATE-S scores
**p < 0.01, ***p < 0.001
Outcome CGI
Baseline
CGI
End of treatment
CGI
Follow-up
RATE-S
Total score
0.46***
n = 88
0.52***
n = 61
0.54***
n = 46
RATE-S
ADHD symptoms
0.41***
n = 88
0.50***
n = 61
0.51***
n = 46
RATE-S
Emotional control
0.31**
n = 88
0.33**
n = 61
0.43**
n = 46
RATE-S
Antisocial scale
0.31**
n = 88
0.13
n = 61
0.43**
n = 46
RATE-S
Social functioning
0.29**
n = 88
0.43**
n = 61
0.23
n = 46
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correlations were found between the CGI and the RATE-S 
Total scale at the end of treatment and at follow-up. This 
demonstrates an important link between illness severity and 
functional impairment. One explanation for the lack of sig-
nificance for the social functioning scale at follow-up may 
be that the CGI relates most well to functional behaviours 
that are associated with clinical syndromes, such as ADHD, 
emotional instability and behavioural control.
A strength of the study is the randomized methodology 
and a reasonable sample size. Additionally the independent 
raters of the CGI were blinded to treatment condition. The 
study’s main limitation is the high dropout rate, which left 
us with a substantially reduced sample at follow-up. Just 
over half of the sample completed the programme. High 
attrition has also been reported in other studies [33, 34].The 
TAU/MED group did not receive any active non-medication 
control intervention as part of the research protocol, which 
may also have inflated the treatment effects in the CBT/
MED group. Nevertheless, all the participants were receiv-
ing medication for ADHD, which in itself should be con-
sidered to be an active control. The patients had all been 
clinically diagnosed with ADHD but from different centres. 
Participants were assessed by the researchers on the MINI 
International Neuropsychiatric Interview at baseline, but did 
not receive any further ADHD clinical assessment. Dosage 
and treatment compliance were not systematically recorded, 
although stability on medication was self-reported.
It is notable that participants presented with a high rate 
of ADHD symptoms—their mean symptom ratings were 
over 10 points higher than those obtained in the RATE 
validation studies (19). This suggests that participants 
were a severely impaired group who may have been poor 
responders to medication. Hence, the combination of the 
R&R2ADHD programme with medication significantly 
improves the treatment effect.
To conclude, the present findings complement our pre-
vious findings and together demonstrate that those indi-
viduals receiving the multimodal treatment of ADHD 
medication plus R&R2ADHD will experience a significant 
reduction in ADHD and comorbid symptoms and that this 
improvement translates into everyday function. The key 
mechanism associated with improved functional outcomes 
is likely to be behavioural control.
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